ArticleWorld journal of psychiatry2025
Comparison of depression risk and depression-related ambulatory care utilization in sarcopenia patients with and without Chinese herbal medicine.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of psychiatric disorder, especially depression, on the prognosis of sarcopenic patients is gaining prominence. Yet, there have been very few studies focusing on this issue, let alone the related targeted mental health prevention. This cohort-based nested case-control study is geared to compare risk of depression and the depression-related ambulatory care utilization for sarcopenia persons with and without receiving add-on Chinese herbal medicines (CHMs) treatment.
aimTo compare risk of depression and the depression-related ambulatory care utilization for sarcopenia persons with and without receiving add-on CHMs treatment.
methodsIn the beginning, we recruited those aged 20-70 years with newly diagnosed sarcopenia and free of depression between 2002 and 2010 from a nationwide insurance database. From them, we identified cases with depression onset occurring after sarcopenia until December 31, 2013. To cautiously isolate the effect of CHMs, we established the matched sets of treated and untreated subjects with CHMs use by randomly frequency matching. A conditional logistic regression was executed to explore the association of CHMs to depression risk, and the frequency and costs of depression-related ambulatory care were compared using Mann-Whitney
resultsAddition of CHMs to routine care of sarcopenia notably correlated with a lower risk of depression. A remarkable effect of CHMs in reducing depression was detected when sarcopenia subjects received CHMs for more than three years, lowering depression risk by as much as 65%. As compared to CHMs users, the non-CHMs users indeed incurred higher frequency and costs of depression-related ambulatory care after depression attack (
conclusionSarcopenic patients can greatly benefit from add-on CHMs treatment, underscoring the urgent need for interdisciplinary collaboration and proactive treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.